Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.
Ball State University · with National Mango Board · NCT07650058
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 35
- US sites recruiting
- 1
- Study start
- February 1, 2026
- Record last updated
- June 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.
Being studied: High-Glycemic Breakfast Containing Cereal and Fresh Mango; High-Glycemic Breakfast Containing Cereal and Table Sugar
Conditions: Healthy Participants
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18 - 45 years.
- Body mass index between 18.5-35.0 kg/m2
- Not pregnant or expecting to become pregnant (females only)
- Not postmenopausal (females only).
- No known chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)
- No history of using tobacco/illicit drugs
- No history of using glucose-lowering medications/supplements.
- No history of using prescribed anti-inflammatory medications
- Does not use over-the-counter anti-inflammatory medications ≥2x/week
- Does not have a pacemaker.
- No relevant food allergies/intolerances
- Able to lay supine for at least ten minutes.
Exclusion Criteria
- Not between the ages of 18-45
- Body mass index \< 18.5 kg/m2 or >35.0 kg/m2
- Pregnant (females only)
- Postmenopausal status (females only).
- Been diagnosed with a chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)
- Uses tobacco products or any illicit drugs.
- Uses glucose-lowering drugs/supplements.
- Regularly takes anti-inflammatory drugs (more than 2x week).
- Have a pacemaker.
- Allergic to mango, wheat, gluten, and/or milk.
- Unable to lay in supine position in the dark for at least ten minutes.
Recruiting US locations
Health Professions Building, Ball State University
Muncie, IN 47306
Site contact: Bryant Keirns, PhD · 765-285-8356 · bryant.keirns@bsu.edu
Study contacts (from the official record)
- Bryant Keirns, PhD · 765-285-8356 · bryant.keirns@bsu.edu
Similar studies in Indiana
All healthy volunteers studies in Indiana →- RecruitingHealthy volunteersEarly Phase 1Overnight stay mentioned
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Indiana University
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Plainfield, IN + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Indianapolis, IN + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Indianapolis, IN + 5 other US sites
- Eligibility basics
- Ages 18+